BNT331

BNT331 is an investigational drug developed by BioNTech for the treatment of bacterial vaginosis. It is currently being evaluated in a first-in-human, two-part, randomized, double-blind, placebo-controlled Phase 1 clinical trial. The study assesses the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT331 when administered as single ascending doses in healthy women and as multiple ascending doses in women diagnosed with bacterial vaginosis. The drug is delivered via self-administered vaginal inserts. As of now, the specific mechanism of action and molecular modality for BNT331 have not been publicly disclosed[1][2][3][4][5][7].